TLR4 and breast cancer: Importantly, LPS sensitizes the therapeutic response of both TNBC and ER+ BC to IAP antagonist therapy by inducing the cancer cell apoptosis through toll-like receptor 4 (TLR4) and MyD88 stimulated TNFα production.